Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Is there a place for corifollitropin alfa in IVF/ICSI cycles? A systematic review and meta-analysis
Fertility and Sterility, Volume 97, No. 4, Year 2012
Notification
URL copied to clipboard!
Description
Objective: To evaluate the role of corifollitropin alfa, a newly developed weekly administrated long-acting recombinant FSH (rFSH), as an alternative for daily rFSH administration in women undergoing controlled ovarian stimulation in GnRH antagonist down-regulated in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI) treatment cycles. Design: Systematic review and meta-analysis of randomized controlled trials. Setting: University and private centers. Patient(s): Infertile women undergoing IVF/ICSI treatment. Intervention(s): Comparing long-acting rFSH corifollitropin alfa versus standard daily administrated rFSH in GnRH antagonist IVF/ICSI cycles. Main Outcome Measure(s): Ongoing pregnancy rate, live birth rate, clinical pregnancy rate, miscarriage rate, duration of stimulation, amount of FSH, number of retrieved oocytes, number of mature oocytes, number of embryos obtained, fertilization rate, ovarian hyperstimulation syndrome (OHSS) incidence, and adverse events. Searches (of literature through November 2011) were conducted in Medline, Embase, Science Direct, the Cochrane Library, and databases of abstracts. Result(s): Four randomized trials involving 2,326 women were included. There was no evidence of a statistically significant difference in ongoing pregnancy rate for corifollitropin alfa versus rFSH. There was evidence of increased ovarian response and risk of OHSS in corifollitropin alfa. Conclusion(s): In view of its equivalence and safety profile, corifollitropin alfa in combination with daily GnRH antagonist seems to be an alternative for daily rFSH injections in normal responder patients undergoing ovarian stimulation in IVF/ICSI treatment cycles. © 2012 by American Society for Reproductive Medicine.
Authors & Co-Authors
Youssef, M. A.F.M.
Egypt, Giza
Cairo University
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Egypt, Cairo
Egyptian International Fertility Ivf-et Center
Van Wely, Madelon
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Aboulfoutouh, Ismail I.
Egypt, Cairo
Egyptian International Fertility Ivf-et Center
El-Khayat, Waleed M.
Egypt, Giza
Cairo University
van der Veen, Fulco V.
Netherlands, Amsterdam
Amsterdam Umc - University of Amsterdam
Al-Inany, Hesham Gaber
Egypt, Giza
Cairo University
Statistics
Citations: 48
Authors: 6
Affiliations: 3
Identifiers
Doi:
10.1016/j.fertnstert.2012.01.092
ISSN:
00150282
e-ISSN:
15565653
Research Areas
Health System And Policy
Maternal And Child Health
Sexual And Reproductive Health
Study Design
Randomised Control Trial
Cohort Study
Study Approach
Systematic review
Participants Gender
Female